Definium Therapeutics Inc.
Definium Therapeutics Inc. (DFTX): 6 pipeline candidates · 5 upcoming catalysts · ~26 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
26.0 months
D/E 0.44 · 5% dilution
Lead: Phase 3
6 candidates
5 upcoming, next in ~136d
0 buys · 6 sells (180d)
A transparent, data-derived signal for Definium Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.7B
Cash
$262.5M
Quarterly Burn
$42.6M
Runway
26.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
248
Total value held
$1.41B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 8,480,230 | $160.3M |
| driehaus capital management llc | 5,911,889 | $111.7M |
| janus henderson group plc | 3,592,483 | $67.9M |
| deep track capital, lp | 3,000,000 | $56.7M |
| geode capital management, llc | 2,495,399 | $47.2M |
| state street corp | 2,471,873 | $46.7M |
| vanguard capital management llc | 2,193,956 | $41.5M |
| commodore capital lp | 2,000,000 | $37.8M |
| fmr llc | 1,809,610 | $34.2M |
| trails edge capital partners, lp | 1,738,110 | $32.9M |
Showing top 10 of 248 institutional holders of Definium Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Definium Therapeutics Inc.'s pipeline?
Definium Therapeutics Inc. (DFTX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Definium Therapeutics Inc.'s lead drug candidate?
Definium Therapeutics Inc.'s most advanced tracked candidate is dt120 (Phase 3) for Major Depressive Disorder.
What is Definium Therapeutics Inc.'s next catalyst?
Definium Therapeutics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a " — expected November 1, 2026.
What is Definium Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Definium Therapeutics Inc. has approximately 26.0 months of cash runway.
What is Definium Therapeutics Inc.'s market capitalization?
Definium Therapeutics Inc.'s market capitalization is approximately $2.7B.
Get the full picture on Definium Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.